Skip to main content
Allogene Therapeutics, Inc. logo

Allogene Therapeutics, Inc. — Investor Relations & Filings

Ticker · ALLO ISIN · US0197701065 US Manufacturing
Open in API
Filings indexed 523 across all filing types
Latest filing 2018-10-05 Regulatory Filings
Country US United States of America
Listing US ALLO

About Allogene Therapeutics, Inc.

https://allogene.com/

Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies. The company engineers T cells from healthy donors to create "off-the-shelf" treatments for cancer and autoimmune diseases. This approach is designed to enable on-demand availability, scalability, and reliability, contrasting with autologous therapies that use a patient's own cells. Allogene's pipeline utilizes multiplex gene-engineering and gene-editing capabilities. Its key investigational programs include cemacabtagene ansegedleucel (cema-cel) for large B-cell lymphoma, ALLO-316 for clear cell renal cell carcinoma, and ALLO-329 for autoimmune disease.

Recent filings

Filing Released Lang Actions
S-1/A
Regulatory Filings Classification · 100% confidence The document is an Amendment No. 3 to a Form S-1 Registration Statement filed with the U.S. Securities and Exchange Commission. It includes detailed information about the registration of securities, indemnification of directors and officers, recent sales of unregistered securities, and other regulatory disclosures related to the securities offering. The Form S-1 is a registration statement used for initial public offerings (IPOs) and other securities offerings, not a financial report like an annual or quarterly report. This document is a regulatory filing related to securities registration and compliance with the Securities Act of 1933. It does not contain financial statements or earnings data but rather legal and regulatory information about the offering. Therefore, the appropriate classification is Regulatory Filings (RNS). The document length (15,000 characters) and content confirm it is not a brief announcement or a report publication announcement but a substantive regulatory filing.
2018-10-05 English
Regulatory Filings 2018
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the SEC Division of Corporation Finance regarding a Registration Statement on Form S-1 filed by Allogene Therapeutics, Inc. It requests acceleration of the effective date of the Registration Statement and discusses distribution of the Preliminary Prospectus to underwriters and investors. The letter is signed by representatives of the underwriters. This is a correspondence related to a securities offering process, specifically a request for acceleration of a registration statement effectiveness under the Securities Act of 1933. It is not a financial report, earnings release, or management discussion. It is a regulatory filing related to the registration and offering process. Given the nature and content, this fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories. The document length is short and it is a letter, not a report or presentation. Therefore, the classification is RNS with high confidence.
2018-10-05 English
Regulatory Filings 2018
Regulatory Filings Classification · 95% confidence The document is a letter from Allogene Therapeutics, Inc. to the SEC requesting acceleration of the effective date of a Registration Statement on Form S-1. It references the Securities Act of 1933 and the registration process for a securities offering. The content is a formal request related to the timing of a registration statement becoming effective, not the registration statement itself or any financial data. The document length is short (1860 characters) and it is a correspondence related to a regulatory filing. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2018-10-05 English
Regulatory Filings 2018
Regulatory Filings Classification · 95% confidence The document is a letter from the company's legal counsel responding to comments from the SEC staff regarding a Registration Statement on Form S-1 filed by Allogene Therapeutics. It discusses amendments to the Registration Statement, responses to SEC comments, and revisions to disclosures in the amended filing. The document is not the Registration Statement itself, nor is it a financial report or earnings release. It is a correspondence letter addressing regulatory review comments, which fits the category of Regulatory Filings (RNS). The document length is about 5,086 characters, which is consistent with a detailed regulatory response letter rather than a full report. Therefore, the appropriate classification is Regulatory Filings (RNS).
2018-10-02 English
S-1/A
Regulatory Filings Classification · 95% confidence The document is a Form S-1/A Registration Statement Amendment No. 2 filed with the U.S. Securities and Exchange Commission. It is a regulatory filing related to the registration of securities for an initial public offering (IPO) by Allogene Therapeutics, Inc. The text includes details about the offering, company overview, risk factors, use of proceeds, capitalization, management discussion and analysis, and other sections typical of an IPO prospectus. This is not a financial report like an annual or quarterly report, nor is it an earnings release or management report. It is a registration statement amendment, which is a regulatory filing related to capital raising and securities registration. Therefore, the appropriate classification is Regulatory Filings (RNS). The document length is substantial (15,000 characters), and it is not merely an announcement of a report but the actual filing document itself.
2018-10-02 English
Regulatory Filings 2018
Regulatory Filings
2018-09-26 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.